Roche’s Virtual Pharma Day

Roche has hosted a virtual event on Tuesday, 14 September 2021.

Pharma strategy, Culture and organization, New technologies
Market opportunities, Launches, Commercial model & Access
Late stage pipeline: Oncology, Neuroscience, Immunology, Ophthalmology, Infectious diseases

Webinar replay

Roche’s Virtual Pharma Day

Additional Information

Investor updates

All

Published on: 17 September 2021

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Published on: 17 September 2021

Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer

Published on: 15 September 2021

Roche opens access to pathology imaging tools to improve patient care

IR events

All

21September

Baader Investment Conference (virtual event)

(CEST)

Munich, DE

add to calendar

23September

Bernstein's 18th Annual Strategic Decisions Conference

(BST)

London, UK

add to calendar

28September

Cantor Global Healthcare 2021 Conference (virtual event)

(EDT)

New York, US

add to calendar

Share price

Latest annual report

Highlights Annual Report 2020

How medicines are making an impact in the lives of patients

Pipeline

Get up-to-date information about our pipeline.

Roche R&D

Genentech Biooncology

Diagnostics news

Roche Diagnostics Investor Day 2021

Sustainability download center

Sustainability at Roche

Non-financial reporting

Dividend calendar

Timetable for the payment of the 2020 dividend

Total return center

Investor tool providing analysis of total returns

FAQ

Get answers to frequently asked questions

Roche’s Virtual Pharma Day

Roche’s Virtual Pharma Day

Additional Information

Related links

Investor updates

Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

Roche presents first phase II data on giredestrant, a next generation selective oestrogen receptor degrader, in untreated oestrogen receptor (ER)-positive, early breast cancer

Roche opens access to pathology imaging tools to improve patient care

IR events

Baader Investment Conference (virtual event)

Bernstein's 18th Annual Strategic Decisions Conference

Cantor Global Healthcare 2021 Conference (virtual event)

Share price

Latest annual report

Highlights Annual Report 2020

Historic quarterly reporting

Finance information tool

Pipeline

Pipeline

Roche R&D

Genentech Biooncology

Diagnostics

Diagnostics news

Roche Diagnostics Investor Day 2021

Sustainability

Sustainability download center

Sustainability at Roche

Non-financial reporting

Dividend and total return

Dividend calendar

Total return center

Frequently asked questions

FAQ

US investors

How to invest

Contact

For all general enquiries

For IR requests

For all general enquiries

For IR requests